Toschi, N;
Lista, S;
Baldacci, F;
Cavedo, E;
Zetterberg, H;
Blennow, K;
Kilimann, I;
... Younsi, N; + view all
(2019)
Biomarker-guided clustering of Alzheimer's disease clinical syndromes.
Neurobiology of Aging
, 83
pp. 42-53.
10.1016/j.neurobiolaging.2019.08.032.
Preview |
Text
Zetterberg_Biomarker-guided clustering of Alzheimer's disease clinical syndromes_VoR.pdf - Published Version Download (1MB) | Preview |
Abstract
Alzheimer's disease (AD) neuropathology is extremely heterogeneous, and the evolution from preclinical to mild cognitive impairment until dementia is driven by interacting genetic/biological mechanisms not fully captured by current clinical/research criteria. We characterized the heterogeneous “construct” of AD through a cerebrospinal fluid biomarker-guided stratification approach. We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ1-42, t-tau, p-tau181, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters. We found 5 distinct clusters (sizes: N = 38, 16, 24, 14, and 21) whose composition was independent of phenotypical groups. Two clusters showed biomarker profiles linked to neurodegenerative processes not associated with classical AD-related pathophysiology. One cluster was characterized by the neuroinflammation biomarker YKL-40. Combining nonlinear data aggregation with informative biomarkers can generate novel patient strata which are representative of cellular/molecular pathophysiology and may aid in predicting disease evolution and mechanistic drug response.
Archive Staff Only
 |
View Item |
